1-1 of 1
Robert Stuart, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.

Mark Levis, MD, PhD, B. Douglas Smith, MD, Miloslav Beran, MD, Maria R. Baer, MD, Harry P. Erba, MD, Larry Cripe, MD, Steven Coutre, MD, Anjali Advani, MD, Alexander Perl, MD, Marcel Devetten, MD, Robert Stuart, MD, Martin S. Tallman, MD, Peter Brown, PhD, Lothar Tremmel, Donald Small, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 403.
https://doi.org/10.1182/blood.V106.11.403.403
Published: 2005